On June 11, 2025, Nuvation Bio Inc. announced FDA approval for IBTROZI (taletrectinib) to treat ROS1-positive non-small cell lung cancer, achieving a confirmed overall response rate of 90% in treatment-naïve patients. The approval is supported by comprehensive clinical trials involving over 300 patients, showcasing significant efficacy and manageable side effects.